1. Scrip
  2. >>Business

Astellas Grows Oncology Portfolio With Ganymed Purchase

 
• By Lubna Ahmed

Astellas Pharma has acquired Ganymed Pharmaceuticals for an upfront cost of €422m to get access to the German firm's cancer antibody pipeline.

To further increase its oncology portfolio, highlighted as one of its core therapy areas and a key driver in its long term sustainable growth, Astellas Pharma Inc. has acquired Ganymed Pharmaceuticals AG, a German biopharma focused on developing immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMAbs).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.